11 Best Gene Therapy Stocks to Buy According to Analysts

3. Bio-Techne Corporation (NASDAQ:TECH)

Price Target Upside: 81.25% 

Bio-Techne Corporation (NASDAQ:TECH), headquartered in Minneapolis, Minnesota, is a leading life sciences company that develops, manufactures, and sells biotechnology products and scientific tools for research, diagnostics, and bioprocessing. The company offers over 500,000 products, including antibodies, proteins, analytical instruments, and molecular diagnostics tools.

Bio-Techne Corporation (NASDAQ:TECH) plays a significant role in gene therapy by providing essential products such as GMP-grade recombinant proteins, specialized cell culture media, and reagents optimized for gene editing tools like CRISPR-Cas9. Their offerings also include analytical tools for characterizing gene therapy products and support for AAV vector production, although this is not a primary focus. The company targets research institutions, biotech companies, and pharmaceutical firms involved in gene therapy, making it one of the most promising companies among the best genomic stocks in the biotech sector.

In its Q4 2024 financial results, Bio-Techne Corporation (NASDAQ:TECH) reported a 2% increase in net sales to $306.1 million, with organic revenue growing 1%. However, GAAP EPS decreased to $0.25 per diluted share, down from $0.47 the previous year, while adjusted EPS also declined. The company’s Protein Sciences segment saw a 4% decrease in sales, while the Diagnostics and Genomics segment grew by 15%. Cash flow from operations increased by 18%, reaching $299.0 million, reflecting strong operational cash generation.

The corporation’s acquisition of Lunaphore, a spatial biology firm, is a strategic move to enhance its position in this rapidly growing field. However, the acquisition and other factors, like unfavorable volume leverage in Protein Sciences, contributed to a decline in profitability, with operating margins for both GAAP and adjusted results decreasing.